Sofie

SOFIE is dedicated to enhancing patient outcomes by developing and delivering innovative molecular diagnostics and therapeutics, known as theranostics. With over 50 years of experience in the field of Positron Emission Tomography (PET), SOFIE has made significant strides in advancing the development of next-generation radiopharmaceuticals. Their commitment to quality and reliability is evident in their comprehensive range of contract manufacturing services, which are designed to meet the clinical needs of healthcare providers through a robust network and a newly established Theranostics Center of Excellence.

The company has created a multi-faceted approach to strengthen the quality of PET programs, ensuring that healthcare professionals can deliver enhanced care to their patients. With 14 network sites dedicated to the timely delivery of radiopharmaceuticals, SOFIE plays a crucial role in diagnosing and treating critical illnesses. Their focus on collaboration with pharmaceutical and academic partners allows them to revolutionize clinical diagnostics and therapeutics, ultimately improving the understanding and treatment of various diseases.

SOFIE's mission is to increase the adoption and application diversity of theranostics by simplifying the technology and making it more accessible. They offer a full line of imaging products and a premier radiopharmacy network, along with contract manufacturing services to supply novel agents for diagnosis and therapy. By harnessing cutting-edge technologies and a dedicated team, SOFIE is committed to making a positive impact on patient health and advancing the future of medical diagnostics and treatment.

Through ongoing scientific collaborations and partnerships, SOFIE continues to push the boundaries of what's possible in the field of radiopharmaceuticals. Their dedication to innovation and quality positions them as a leader in the industry, striving to improve patient lives with every advancement they make.